CADTH

Record of Amendments to "Drugs for Chronic Hepatitis C Infection: Recommendations Report"

Change #	Page	November 2015 version	Revised (June 2016) version
1	14, paragraph 4	The review included 67 new publications describing 63 unique studies, in addition to 10 studies from the previous Therapeutic Review…	The review included 63 new publications describing 67 unique studies, in addition to 10 studies from the previous Therapeutic Review…
2	16, Table 1 (row 2, column 2)	18 studies; 3,594 participants	17 studies; 3,594 participants
3	16, paragraph 4	This analysis included 26 studies and a total of 4,146 participants.	This analysis included 22 studies and a total of 4,146 participants.
4	16, paragraph 5	Results of the subgroup analyses were generally consistent with those for the overall treatment-experienced population in that no significant differences in SVR were found in most subgroups when LDV + SOF for 12 weeks and PAR/RIT + OMB + DAS ± RBV for 12 weeks were compared against each other.	Results of the subgroup analyses were generally consistent with those for the overall treatment-experienced population in that no significant differences in SVR were found in all but two subgroups when LDV + SOF for 12 weeks and PAR/RIT + OMB + DAS ± RBV for 12 weeks were compared against each other.
5	17, paragraph 1	One exception was the subgroup analysis of patients without cirrhosis, in which PAR/RIT + OMB + DAS + RBV for 12 weeks significantly improved SVR compared with LDV + SOF for 12 weeks.	One exception was the subgroup analysis of patients without cirrhosis, in which PAR/RIT + OMB + DAS + RBV for 12 weeks significantly improved SVR compared with LDV + SOF for 12 weeks, and the second was the subgroup analysis of patients with genotype 1b infection, in which PAR/RIT + OMB + DAS for 12 weeks significantly improved SVR compared with LDV + SOF for 12 weeks.
6	17, Table 2 (row 2, column 2)	12 studies; 1,683 participants	10 studies; 1,683 participants
7	17, Table 2 (row 3, column 2)	17 studies; 2,135 participants	15 studies; 2,053 participants
8	17, Table 2 (row 3, column 3)	PAR/RIT + OMB + DAS + RBV for 12 weeks significantly improved SVR compared with LDV + SOF for 12 weeks. However, the same regimen without RBV did not significantly improve SVR.	PAR/RIT + OMB + DAS for 12 weeks significantly improved SVR compared with LDV + SOF for 12 weeks.
9	17, Table 2 (row 4, column 2)	14 studies; 850 participants	15 studies; 850 participants
10	17, Table 2 (row 5, column 2)	19 studies; 3,038 participants	16 studies; 3,038 participants
11	17, Table 2 (row 9, column 2)	17 studies; 1,403 participants	13 studies; 1,403 participants
12	17, Table 2 (row 10)	Genotype 1a, treatment-experienced with prior null response…	Entire row deleted